



For the promotion  
and recognition  
of excellence  
in orphan diseases  
treatment research

#### The Review Committee

**Chairman:**

**Prof. Robert J. Desnick,**  
M.D., PhD., D.S.C. (Hon),

Dean for Genetics and Genomic  
Medicine, Professor and Chairman  
Emeritus Department of Genetics  
& Genomic Sciences, The Icahn  
School of Medicine at Mount Sinai,  
New York City, NY, USA

**Prof. Andrew Pearson,**  
M.D., PhD.,

Retired Cancer Research  
Professor of Paediatric Oncology,  
Institute of Cancer Research and  
the Royal Marsden Hospital NHS  
Trust, Sutton, UK

**Prof. Charles Patrick Reynolds**  
M.D., PhD.,

Cancer Center Director,  
Professor of Pediatrics,  
Cell Biology & Biochemistry,  
and internal medicine,  
School of Medicine, Texas  
Tech University Health Sciences  
Center, Lubbock, USA

To submit an Application:  
[www.prize.recordati.it](http://www.prize.recordati.it)

Contacts:  
[recordatiprize2024@recordati.com](mailto:recordatiprize2024@recordati.com)

Recordati S.p.A  
Via M. Civitali, 1  
20148 Milan, Italy  
Ph +39 02 48787.1  
Fax +39 02 40 073 747  
[www.recordati.com](http://www.recordati.com)

## LAUNCH OF THE 11<sup>TH</sup> EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH

The 2024 Award will be dedicated to the promotion and recognition of excellence in research within pediatric oncology, specifically neuroblastoma. The winning project will be awarded with a € 100,000 research grant.

Milan, May 19<sup>th</sup>, 2023

The launch of the call for applications to the eleventh edition of the International Prize for Scientific Research Arrigo Recordati was announced yesterday during the Advances Neuroblastoma Research Meeting.

The 2024 Award will be dedicated to the promotion and recognition of excellence in research within pediatric oncology, specifically neuroblastoma, reflecting Recordati's strong commitment to rare diseases through its division Recordati Rare Diseases.

The winning project will be awarded with a € 100,000 research grant.

The Prize was established in 2000 by Recordati Group in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati to perpetuate his legacy and to inspire biomedical discoveries benefiting people worldwide. Arrigo Recordati strongly believed in the power of the research to drive the development of the pharmaceutical industry and provide products beneficial to public health and individual wellbeing.

*"I am proud that we are able to focus on such an important topic for the 11<sup>th</sup> edition of the International Prize for Scientific Research Arrigo Recordati - pediatric oncology, specifically neuroblastoma, which is a rare devastating condition for the children diagnosed with it and for their families. This is a testimony once again of our strong commitment to support innovation and research within rare diseases",* said **Andrea Recordati, Chairman at Recordati.**

Young investigators of all nationalities working in the area of pediatric neuroblastoma are eligible to apply, with the selected projects reviewed by an independent panel of internationally recognised rare disease experts.

Learn more about the 2024 Award here: [www.prize.recordati.it](http://www.prize.recordati.it)



**For the promotion  
and recognition  
of excellence  
in orphan diseases  
treatment research**

### The Review Committee

#### Chairman:

**Prof. Robert J. Desnick,**  
M.D., PhD., D.SC. (Hon),

Dean for Genetics and Genomic  
Medicine, Professor and Chairman  
Emeritus Department of Genetics  
& Genomic Sciences, The Icahn  
School of Medicine at Mount Sinai,  
New York City, NY, USA

**Prof. Andrew Pearson,**  
M.D., PhD.,

Retired Cancer Research  
Professor of Paediatric Oncology,  
Institute of Cancer Research and  
the Royal Marsden Hospital NHS  
Trust, Sutton, UK

**Prof. Charles Patrick Reynolds**  
M.D., PhD.,

Cancer Center Director,  
Professor of Pediatrics,  
Cell Biology & Biochemistry,  
and internal medicine,  
School of Medicine, Texas  
Tech University Health Sciences  
Center, Lubbock, USA

To submit an Application:  
[www.prize.recordati.it](http://www.prize.recordati.it)

Contacts:  
[recordatiprize2024@recordati.com](mailto:recordatiprize2024@recordati.com)

Recordati S.p.A  
Via M. Civitali, 1  
20148 Milan, Italy  
Ph +39 02 48787.1  
Fax +39 02 40 073 747  
[www.recordati.com](http://www.recordati.com)

### **2024 Review Committee and Application Procedure**

For the 2024 Award, the Review Committee is chaired by **Prof. Robert J. Desnick**, M.D., PhD., D.SC. (Hon), Dean for Genetics and Genomic Medicine, Professor and Chairman Emeritus Department of Genetics & Genomic Sciences, The Icahn School of Medicine at Mount Sinai, New York City, NY, USA. The other members of the panel are **Prof. Andrew Pearson**, M.D., PhD., Retired Cancer Research Professor of Paediatric Oncology, Institute of Cancer Research and the Royal Marsden Hospital NHS Trust, Sutton, UK, and **Prof. Charles Patrick Reynolds**, M.D., PhD., Cancer Center Director, Professor of Pediatrics, Cell Biology & Biochemistry, and internal medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.

The Review Committee will assess and select the winning project based on the quality of the proposed research. Basic, translational, preclinical, and clinical research projects focusing on neuroblastoma are eligible.

Applicants should be independent junior faculty who are not more than ten years from their terminal degree or eight years from the end of their fellowship and who are not employed full-time with a pharmaceutical company.

The Application Procedure will follow a two-step selection approach. The deadline to submit initial proposals is September 30<sup>th</sup>, 2023 (Preselection Phase), while Full Applications must be submitted by February 28<sup>th</sup>, 2024.

**The winning project will be formally announced during an Award Ceremony at SIOP Europe Congress (International Society of Pediatric Oncology Europe) held in Italy from May 13<sup>th</sup> to 17<sup>th</sup>, 2024.**

Recordati recognises the value of basic research to elucidate the pathophysiology and the etiology of pediatric neuroblastoma, translational research to develop new diagnostic and therapies for early intervention, and clinical research to develop novel therapeutic strategies. Such research projects are sought for this competition.

Proposals should be based on strong preliminary results which support the project rationale. If a proposed experimental treatment is based on a pre-existing treatment, the project is eligible only if the treatment is being repurposed from another indication or if its formulation, or administration is changed in a major way, to improve treatment quality, compliance, efficacy, safety, or any other significant patient benefit. Intellectual Property Rights, when relevant, will be safeguarded. Previous research activity and publications will be a major component for the assessment of proposals.



**For the promotion  
and recognition  
of excellence  
in orphan diseases  
treatment research**

### The Review Committee

**Chairman:**

**Prof. Robert J. Desnick,**  
M.D., PhD., D.Sc. (Hon),

Dean for Genetics and Genomic  
Medicine, Professor and Chairman  
Emeritus Department of Genetics  
& Genomic Sciences, The Icahn  
School of Medicine at Mount Sinai,  
New York City, NY, USA

**Prof. Andrew Pearson,**  
M.D., PhD.,

Retired Cancer Research  
Professor of Paediatric Oncology,  
Institute of Cancer Research and  
the Royal Marsden Hospital NHS  
Trust, Sutton, UK

**Prof. Charles Patrick Reynolds**  
M.D., PhD.,

Cancer Center Director,  
Professor of Pediatrics,  
Cell Biology & Biochemistry,  
and internal medicine,  
School of Medicine, Texas  
Tech University Health Sciences  
Center, Lubbock, USA

**To submit an Application:**  
[www.prize.recordati.it](http://www.prize.recordati.it)

**Contacts:**  
[recordatiprize2024@recordati.com](mailto:recordatiprize2024@recordati.com)

**Recordati S.p.A**  
Via M. Civitali, 1  
20148 Milan, Italy  
Ph +39 02 48787.1  
Fax +39 02 40 073 747  
[www.recordati.com](http://www.recordati.com)

### **Recordati Rare Diseases: Focused on the Few**

Recordati Rare Diseases, is focused on providing the most effective treatment for people living with rare diseases, forming part of the Recordati Group - a public international specialty pharmaceutical company dedicated to the research, development, manufacturing and marketing of medicines which improve the lives of patients and their families. At Recordati Rare Diseases, we are “Focused on the few”, with a mission to reduce the impact of rare and devastating diseases by providing urgently needed therapies.

Recordati develops, produces, and markets drugs for the treatment of rare diseases through Recordati Rare Diseases, a group of companies operating globally and dedicated entirely to serve patients suffering from these diseases. Historically focused on rare genetic metabolic illnesses, the Group’s portfolio in this segment was expanded with the acquisition of additional important treatments for rare endocrine diseases and rare oncological diseases.

Sharing the conviction that every person with a rare disease has the right to the best possible treatment, Recordati Rare Diseases works closely with specialists, healthcare professionals, associations, patients and caregivers to spread knowledge, improve diagnosis and treatment, and enable access to care.

Recordati Rare Diseases is also committed to supporting patients and their families affected by rare diseases through the research and development of new therapies and the distribution of specific scientific knowledge throughout the medical community.

***Recordati** (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan, Australia and New Zealand, China and South Korea. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business operating globally and dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2022 was €1,853.3 million, operating income was €437.3 million and net income was €312.3 million.*

Further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

For more information:

Investor Relations & Corporate  
Communications

Federica De Medici  
(39) 02 48787146

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Press Office

Brunswick: Barbara Scalchi / Andrea Mormandi  
(39) 02 9288 6200

e-mail: [recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)